The next step is to investigate whether the suppressive effect of LEV on microglial inflammation via AP-1 inhibition can improve neurological disorders other than epilepsy, which are accompanied by microglial activation and neuroinflammation as pathology. The gene discussed is FOS; the disease is epilepsy.